← All countries · Europe
87%
MCV1
2025 · WHO/UNICEF estimate
90%
DTP3
2025 · WHO/UNICEF estimate
90%
IPV complete
2025 · WHO/UNICEF estimate
90%
HepB3
2025 · WHO/UNICEF estimate
51
Measles cases
2025 reported
348
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 18%2016 · WHO/UNICEF estimate | 20% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 90%2025 · WHO/UNICEF estimate | — | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 90%2025 · WHO/UNICEF estimate | 90.1% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 93%2025 · WHO/UNICEF estimate | — | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 90%2025 · WHO/UNICEF estimate | 90.1% | C · weak | |
| MCV1First dose of measles-containing vaccine | 87%2025 · WHO/UNICEF estimate | 87.0% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 87%2025 · WHO/UNICEF estimate | 87.3% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 87%2025 · WHO/UNICEF estimate | 87.0% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 90%2025 · WHO/UNICEF estimate | 90.0% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 90%2025 · WHO/UNICEF estimate | 90.0% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | no data |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 81%2025 · WHO/UNICEF estimate | 81.3% | A · strong | |
| RotaCRotavirus vaccine, complete series | 86%2025 · WHO/UNICEF estimate | 85.6% | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 76%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 76%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 74%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 512025 | 9.6per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 1202025 | 22.6per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 3482025 | 65.6per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 602025 | 11.3per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 152025 | 2.8per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (50 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | Risk group(s) | Child and adult risk groups. In 2015, the National Immunisation Advisory Committee (NIAC) and the Health Information and Quality Authority (HIQA) both recommended that BCG vaccine does not need to be given to all children in Ireland. Currently BCG is not part of the immunisation schedule in Ireland. | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | M13 | General/routine | For babies born from 01/10/2024 a 4th dose at 13 months is included in the schedule (they will be 13 months from 01.11.2025 onwards) |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | Y4 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | Risk groups (including healthcare workers) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | Risk groups (including healthcare workers) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | Risk groups (including healthcare workers) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | Risk groups (including healthcare workers) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M5 | Health workers | Risk groups (including healthcare workers) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M5 | Risk group(s) | Risk groups (including healthcare workers) |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | Risk groups |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | Risk groups |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | +M5 | Risk group(s) | Risk groups |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | Risk groups | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12 | HPV administered to females and males | From 2019, switched to HPV9 and to females and males in first year of secondary school. Since November 2022 a single dose of HPV vaccine is recommended in Ireland for those aged 9-24 years who are immunocompetent as there is now sufficient evidence that there is no significant difference in vaccine effectiveness between those aged nine to 24 years of age who are immunocompetent who receive one, two, or three vaccine doses. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons >=60 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Y12 | General/routine | |
| MEN_BMeningococcal B vaccine | 1 | M2 | General/routine | |
| MEN_BMeningococcal B vaccine | 2 | M4 | General/routine | |
| MEN_BMeningococcal B vaccine | 3 | M12 | General/routine | |
| MEN_C_CONJMeningococcal C conjugate vaccine | 1 | M6 | General/routine | Men ACWY-135 conjugate to replace MenC at Y12 from February 2020. For babies born from 01/10/2024 the menC at 6 months has been removed from the schedule |
| MEN_C_CONJMeningococcal C conjugate vaccine | 2 | M13 | General/routine | Men ACWY-135 conjugate to replace MenC at Y12 from February 2020. For babies born from 01/10/2024 the menC at 6 months has been removed from the schedule |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Note that for babies born from 01.10.2024, the second dose will be given as MMRV (MMR and Varicella). This will be at age 4-5Y i.e. in 2029 |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Health workers | Health care workers | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Risk group(s) | Risk groups, outbreaks | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y4-Y5 | General/routine | Note that for babies born from 01.10.2024, the second dose will be given as MMRV (MMR and Varicella). This will be at age 4-5Y i.e. in 2029 |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | Y4-Y5 | General/routine | Babies born from 01.10.2024, the second dose will be given as MMRV (MMR and Varicella). This will be at age 4-5Y i.e. in 2029 |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M13 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y65 | Adults | and child risk groups >2 years and adult risk groups |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y2 | Risk group(s) | Child risk groups >2 years and adult risk groups |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | General/routine | Newborns born between 01/09/2025 to 28/02/2026, Catch up campaign conducted between 01/09/2025 and 14/12/2025 on infants born between 01/03/2025 and 31/08/2025 | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women from 16 weeks gestation | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Risk group(s) | Risk groups as per recommendations | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 5 | Y12-Y13 | General/routine | |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine | Varicella vaccine was added to the Primary Childhood Immunisation Schedule in 2024 for babies born on or after October 1st 2024. Varicella vaccine included in the schedule for babies born from 01/10/2024 to be given at 12 months and a 2nd dose at 4-5 years |
| VARICELLAVaricella vaccine | 2 | Y4-Y5 | General/routine | Varicella vaccine was added to the Primary Childhood Immunisation Schedule in 2024 for babies born on or after October 1st 2024. Varicella vaccine included in the schedule for babies born from 01/10/2024 to be given at 12 months and a 2nd dose at 4-5 years |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.